Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia (Q34622576)

3 August 2017

1 reference

title

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia (English)

1 reference

3 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Andreas Hochhaus

4

0 references

author name string

Ellen Weisberg

1

1 reference

3 August 2017

Paul W Manley

2

1 reference

3 August 2017

Sandra W Cowan-Jacob

3

1 reference

3 August 2017

James D Griffin

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

3 August 2017

Nature Reviews Cancer

1 reference

3 August 2017

7

1 reference

3 August 2017

5

1 reference

3 August 2017

345-356

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2126

3 August 2017

0 references

cites work

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

31 March 2020

1 reference

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

31 March 2020

1 reference

A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia

31 March 2020

1 reference

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

31 March 2020

1 reference

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

31 March 2020

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

31 March 2020

1 reference

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

31 March 2020

1 reference

Imatinib: a selective tyrosine kinase inhibitor

31 March 2020

1 reference

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

31 March 2020

1 reference

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

31 March 2020

1 reference

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

31 March 2020

1 reference

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

31 March 2020

1 reference

31 March 2020

Autoinhibition of c-Abl

1 reference

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

31 March 2020

1 reference

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

31 March 2020

1 reference

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

31 March 2020

1 reference

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

31 March 2020

1 reference

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

31 March 2020

1 reference

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

31 March 2020

1 reference

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

31 March 2020

1 reference

Two different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case report

31 March 2020

1 reference

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

31 March 2020

1 reference

Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.

31 March 2020

1 reference

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

31 March 2020

1 reference

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

31 March 2020

1 reference

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

31 March 2020

1 reference

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

31 March 2020

1 reference

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

31 March 2020

1 reference

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

31 March 2020

1 reference

Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells

31 March 2020

1 reference

Dynamics of chronic myeloid leukaemia.

31 March 2020

1 reference

Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.

31 March 2020

1 reference

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

31 March 2020

1 reference

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

31 March 2020

1 reference

Fusion tyrosine kinases: a result and cause of genomic instability

31 March 2020

1 reference

The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells

31 March 2020

1 reference

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

31 March 2020

1 reference

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

31 March 2020

1 reference

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

31 March 2020

1 reference

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

31 March 2020

1 reference

An efficient rapid system for profiling the cellular activities of molecular libraries.

31 March 2020

1 reference

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

31 March 2020

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

31 March 2020

1 reference

Src family tyrosine kinases and growth factor signaling

31 March 2020

1 reference

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

31 March 2020

1 reference

2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (d

31 March 2020

1 reference

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

31 March 2020

1 reference

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib

31 March 2020

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

31 March 2020

1 reference

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

31 March 2020

1 reference

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

31 March 2020

1 reference

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

31 March 2020

1 reference

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

31 March 2020

1 reference

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

31 March 2020

1 reference

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

31 March 2020

1 reference

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor

31 March 2020

1 reference

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

31 March 2020

1 reference

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

31 March 2020

1 reference

Aurora-kinase inhibitors as anticancer agents

31 March 2020

1 reference

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

31 March 2020

1 reference

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

31 March 2020

1 reference

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

31 March 2020

1 reference

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

31 March 2020

1 reference

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

31 March 2020

1 reference

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

31 March 2020

1 reference

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

31 March 2020

1 reference

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

31 March 2020

1 reference

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor

31 March 2020

1 reference

In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations

31 March 2020

1 reference

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2126

1 reference

Dimensions Publication ID

3 August 2017

1041504094

0 references

Fatcat ID

release_3jfek75pibetfb4oaatuobe6eq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3jfek75pibetfb4oaatuobe6eq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference